Clinical Trials Logo

Clinical Trial Summary

Aortic dissection is a deadly and dangerous disease. About 28% of patients with ascending aortic dissection can't tolerate open surgical trauma caused by thoracotomy and cardiopulmonary bypass, and the prognosis is poor. Minimally invasive endovascular treatment has been applied in the treatment of descending aortic dissection. However, due to the special anatomical structure and high speed /pressure blood flow, the treatment of ascending aorta dissection has become an international difficulty.


Clinical Trial Description

This study was designed combination of retrospective and prospective methods, and focused on distal false lumen Aneurysmal Expansion of Aortic Dissection (DAEAD) . To formulate clinical data for the risk assessment of DAEAD, and best intracavitary treatment or long-term efficacy evaluation, we combined the results of genetic testing, evaluating the missense mutation, computer simulation of blood flow dynamics analysis, and clinical imaging analysis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04544579
Study type Observational
Source Chinese Medical Association
Contact Zaiping Jing, professor
Phone 02131161670
Email xueguanky@163.com
Status Not yet recruiting
Phase
Start date October 1, 2020
Completion date September 30, 2022

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT00583817 - Endovascular Treatment of Thoracic Aortic Disease N/A
Enrolling by invitation NCT05927090 - Outcomes of Type A Aortic Dissection Repair
Recruiting NCT03917862 - Strategy for Aortic Surgery Hemostasis Phase 2/Phase 3